Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
100.60
-0.79 (-0.78%)
At close: Dec 30, 2025, 4:00 PM EST
102.56
+1.96 (1.95%)
After-hours: Dec 30, 2025, 7:04 PM EST
Guardant Health Stock Forecast
Stock Price Forecast
The 21 analysts that cover Guardant Health stock have a consensus rating of "Strong Buy" and an average price target of $96.48, which forecasts a -4.10% decrease in the stock price over the next year. The lowest target is $55 and the highest is $155.
Price Target: $96.48 (-4.10%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 8 | 8 | 8 |
| Buy | 10 | 10 | 14 | 15 | 15 | 13 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 21 | 23 | 23 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $100 → $125 | Strong Buy | Maintains | $100 → $125 | +24.25% | Dec 22, 2025 |
| Mizuho | Mizuho | Buy Maintains $100 → $120 | Buy | Maintains | $100 → $120 | +19.28% | Dec 17, 2025 |
| Barclays | Barclays | Buy Maintains $85 → $120 | Buy | Maintains | $85 → $120 | +19.28% | Dec 15, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $115 → $155 | Buy | Maintains | $115 → $155 | +54.08% | Dec 15, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $90 → $120 | Buy | Maintains | $90 → $120 | +19.28% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
997.66M
from 739.02M
Increased by 35.00%
Revenue Next Year
1.27B
from 997.66M
Increased by 26.80%
EPS This Year
-2.36
from -3.56
EPS Next Year
-2.39
from -2.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.0B | 1.4B | ||||
| Avg | 997.7M | 1.3B | ||||
| Low | 946.0M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 38.0% | 39.4% | ||||
| Avg | 35.0% | 26.8% | ||||
| Low | 28.0% | 14.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.83 | -1.17 | ||||
| Avg | -2.36 | -2.39 | ||||
| Low | -3.04 | -3.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.